AbCellera Biologics (ABCL) vs ACADIA Pharmaceuticals (ACAD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 176.1% versus a loss of 27.4%. Over five years, ACAD leads with a -8.9% price change compared with -30.7% for ABCL. AbCellera Biologics is the larger company by market cap ($3.16 billion vs $2.96 billion), about 1.1 times the size.
ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | ACAD |
|---|---|---|
| Share price | $9.69 | $17.11 |
| Market cap | $3.16B | $2.96B |
| 1-day change | -7.45% | -2.73% |
| YTD return | +183.33% | -35.94% |
| 1-year return | +176.07% | -27.38% |
| 5-year return | -30.74% | -8.94% |
| P/E ratio (TTM) | — | 8.07 |
| Forward P/E | — | 15.75 |
| EPS (TTM) | $-0.48 | $2.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $1.07B |
| Revenue growth (YoY) | +160.56% | +11.87% |
| Net income (latest FY) | $-146.41M | $391.00M |
| Gross margin | — | 91.69% |
| Operating margin | -288.98% | 9.78% |
| Net margin | -194.88% | 36.49% |
| 52-week high | $15.02 | $30.96 |
| 52-week low | $2.75 | $15.86 |
| Distance from 52-week high | -35.46% | -44.74% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +92.67% | +77.21% |
| Average volume | 4.34M | 2.18M |
| Shares outstanding | 326.62M | 172.83M |
| Employees | 562 | 796 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed ACAD by 203.4 percentage points over the past year.
- ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +11.87%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
ABCL vs ACAD FAQ
Which is bigger, AbCellera Biologics or ACADIA Pharmaceuticals?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.16B compared with $2.96B for ACADIA Pharmaceuticals (ACAD).
Which stock has performed better over the past year, ABCL or ACAD?
ABCL returned +176.07% over the past 12 months, compared with -27.38% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and ACADIA Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.